Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defective Host Immunity in a Mouse Hindlimb Ischemia Model Attenuates the Blood Flow Recovery Promoted by an mRNA/LNP Formulation.

Molecular pharmaceutics·2025
Same author

mRNA-based <i>in vivo</i> induction of ETV2 to restore blood flow in a preclinical mouse hindlimb ischemia model.

Molecular therapy. Nucleic acids·2025
Same author

A novel anti-NGF PEGylated Fab' provides analgesia with lower risk of adverse effects.

mAbs·2022
Same author

ASP7266, a Novel Antibody against Human Thymic Stromal Lymphopoietin Receptor for the Treatment of Allergic Diseases.

The Journal of pharmacology and experimental therapeutics·2021
Same author

AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys.

Biologicals : journal of the International Association of Biological Standardization·2020
Same author

[A Case Treated with Selective Embolization for Hemorrhage during Tonsillectomy].

Nihon Jibiinkoka Gakkai kaiho·2018
Same journal

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same journal

The Role of Salivary Microbiota in Pancreatic Cancer: From Screening to Tumor Progression and Treatment Response.

Biomedicines·2026
Same journal

Diagnostic Utility of Surface Electromyography for Identifying Muscles Affected by Myofascial Trigger Points: A Scoping Review.

Biomedicines·2026
Same journal

Performance Assessment of a Locally Semi-Automated NGS-Based Workflow for Homologous Recombination Deficiency Testing in High-Grade Serous Ovarian Carcinoma.

Biomedicines·2026
Same journal

Coupling and Uncoupling Pleiotropy Between Hypertension and Type 2 Diabetes Contribute to Exploring Potential Heterogeneity in Cardiovascular Risk in East Asian Population.

Biomedicines·2026
Same journal

Maternal Response to Therapeutic Plasma Exchange in Early Gestation: A Case Series of Thrombotic Microangiopathies and Neurological Disorders.

Biomedicines·2026
See all related articles

Related Experiment Video

Updated: Jan 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Th2 Suppression Through Antigen Liver Expression Using mRNA-LNP Technology.

Kazunori Arai1, Hanae Toyonaga2, Lei Cheng3

  • 1Astellas Pharma, Inc., Tsukuba 305-8585, Japan.

Biomedicines
|September 27, 2025
PubMed
Summary
This summary is machine-generated.

Messenger RNA-lipid nanoparticle (mRNA-LNP) technology can suppress allergic airway inflammation. This study shows mRNA-LNP delivery of antigens to liver tissue reduces Th2 cytokines and increases regulatory T cells in mice.

Keywords:
Th2 suppressionliver antigen expressionmRNA-LNP

More Related Videos

Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

8.2K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.2K

Related Experiment Videos

Last Updated: Jan 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K
Cell Type-specific Gene Expression Profiling in the Mouse Liver
10:06

Cell Type-specific Gene Expression Profiling in the Mouse Liver

Published on: September 17, 2019

8.2K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.2K

Area of Science:

  • Immunology
  • Gene Therapy
  • Allergy Research

Background:

  • Messenger RNA-lipid nanoparticle (mRNA-LNP) is an advanced nucleic acid delivery system.
  • While mRNA vaccines are in clinical development, mRNA-LNP applications for allergies are under investigation.
  • This study explores mRNA-LNP's potential to suppress immune responses in liver tissue for allergy treatment.

Purpose of the Study:

  • To evaluate the efficacy of mRNA-LNP technology in suppressing immune responses related to allergies.
  • To determine if expressing antigens in mouse liver tissue via mRNA-LNP can mitigate allergic inflammation.

Main Methods:

  • Ovalbumin (OVA) antigen-expressing mRNA was synthesized and encapsulated into LNPs (OVA-mRNA-LNP).
  • The OVA-mRNA-LNP was tested in an OVA-sensitized mouse model, assessing splenocyte cytokine production and regulatory T cell (Treg) populations ex vivo.
  • Prophylactic and therapeutic administration of OVA-mRNA-LNP was evaluated in an OVA-induced airway inflammation model.

Main Results:

  • OVA-mRNA-LNP administration led to suppressed Th2 cytokines (IL-4, IL-5) and increased Treg populations in stimulated splenocytes.
  • Significant reduction (40-80%) in Th2 cytokines was observed in Bronchoalveolar Lavage Fluid (BALF) following both prophylactic and therapeutic OVA-mRNA-LNP treatment.
  • These findings indicate successful modulation of the immune response against the allergen.

Conclusions:

  • Messenger RNA-lipid nanoparticle technology represents a safe, non-viral gene delivery method.
  • Antigen expression in liver tissue using mRNA-LNP is a viable strategy for suppressing allergen-induced inflammation.
  • This approach holds promise for managing allergic diseases.